Lin Cheng-Yao, Hsiao Sheng-Yen, Huang Wen-Tsung, Tsao Chao-Jung, Ho Chung-Han, Su Shih-Bin, Guo How-Ran
Division of Hematology-Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Department of Senior Welfare and Services, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
Front Oncol. 2023 Jan 9;12:1047684. doi: 10.3389/fonc.2022.1047684. eCollection 2022.
Breast cancer (BC) is the most common cancer in women worldwide. Because of the extended survival of patients with BC, the occurrence of second primary malignancies (SPMs) after BC is an important issue.
We identified female patients with BC in the Breast Cancer Health Database of Taiwan, which includes four cancer registry datasets between 2002 and 2014 from Taiwan Cancer Registry. We compared the incidence of SPM between patients who received chemotherapy and/or radiotherapy with those who did not. Stratified analyses were performed according to the American Joint Committee on Cancer (AJCC) stage. The Cox regression model was used to identify the risk factors for SPM and evaluate their effects.
We enrolled 85,947 eligible patients with BC, and 2,656 (3.09%) patients developed SPM. The median duration of SPM was 2.70 (1.14-5.14) years. Radiotherapy was administered in 40,946 (47.64%) patients, and chemotherapy was administered in 52,120 (60.64%). The most common SPMs were digestive tract cancers (876, 31.89%). The risk factors for SPM included the AJCC stage, chemotherapy, radiotherapy, age, and underlying comorbidities. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in any stage. In contrast, after adjusting for other risk factors, patients at stage III/IV who received both therapies had lower risks of SPM compared with those who did not ( = 0.047).
The risk of SPM was different across BC stages. Neither chemotherapy nor radiotherapy was associated with an increased risk of SPM in women with BC.
乳腺癌(BC)是全球女性中最常见的癌症。由于BC患者生存期延长,BC后发生第二原发性恶性肿瘤(SPM)是一个重要问题。
我们在台湾乳腺癌健康数据库中识别出BC女性患者,该数据库包含2002年至2014年来自台湾癌症登记处的四个癌症登记数据集。我们比较了接受化疗和/或放疗的患者与未接受化疗和/或放疗的患者之间SPM的发生率。根据美国癌症联合委员会(AJCC)分期进行分层分析。采用Cox回归模型确定SPM的危险因素并评估其影响。
我们纳入了85947例符合条件的BC患者,其中2656例(3.09%)发生了SPM。SPM的中位持续时间为2.70(1.14 - 5.14)年。40946例(47.64%)患者接受了放疗,52120例(60.64%)患者接受了化疗。最常见的SPM是消化道癌症(876例,31.89%)。SPM的危险因素包括AJCC分期、化疗、放疗、年龄和基础合并症。在任何分期中,化疗和放疗均与SPM风险增加无关。相比之下,在调整其他危险因素后,III/IV期接受两种治疗的患者与未接受两种治疗的患者相比,SPM风险更低(P = 0.047)。
BC各分期的SPM风险不同。化疗和放疗均与BC女性患者SPM风险增加无关。